1.浙江省杭州市中医院,浙江省杭州市体育场路453号,310007
2.浙江中医药大学 附属第一医院
3.浙江中医药大学第一临床医学院
qindp19841@sina.com,(0571)87068001
收稿:2020-07-06,
修回:2021-08-24,
纸质出版:2021-10-17
移动端阅览
魏霞,钦丹萍,王耀东等.承气汤类方对重症急性胰腺炎肠功能作用及预后的网状Meta分析[J].中医杂志,2021,62(20):1827-1836.
WEI Xia,QIN Danping,WANG Yaodong,et al.Effect of Chengqi Decoction (承气汤) Series on Intestinal Function and Prognosis of Severe Acute Pancreatitis: Network Meta-analysis[J].Journal of Traditional Chinese Medicine,2021,62(20):1827-1836.
魏霞,钦丹萍,王耀东等.承气汤类方对重症急性胰腺炎肠功能作用及预后的网状Meta分析[J].中医杂志,2021,62(20):1827-1836. DOI: 10.13288/j.11-2166/r.2021.20.014.
WEI Xia,QIN Danping,WANG Yaodong,et al.Effect of Chengqi Decoction (承气汤) Series on Intestinal Function and Prognosis of Severe Acute Pancreatitis: Network Meta-analysis[J].Journal of Traditional Chinese Medicine,2021,62(20):1827-1836. DOI: 10.13288/j.11-2166/r.2021.20.014.
目的
2
系统评价承气汤类方不同给药途径及给药时间对重症急性胰腺炎(SAP)肠功能的作用及对患者预后的影响。
方法
2
检索PubMed、Embase、Cochrane Library、Web of science、中国生物医学文献数据库、万方数据知识服务平台、中国知网、维普数据库,检索时间为建库至2020年1月31日。采用Cochrane手册6.0推荐的偏倚风险评价工具对纳入文献进行质量评价,采用R 3.6.3和Stata 15对主要结局(首次排便时间、肠功能恢复时间)及次要结局[腹腔内压、治疗后C反应蛋白值、感染率、多器官功能障碍综合征(MODS)发生率、有效率和死亡率]进行分析,采用曲线下面积(SUCRA)对干预措施进行排序,采用Egger's、Begg's检验检测发表偏倚。
结果
2
共纳入27篇随机对照试验,包含1825例患者,6种治疗方法,包括西医常规措施、西医常规措施联合承气汤类方早期经口给药(口服或胃肠营养管注入)、联合早期灌肠、联合早期经口给药加灌肠、联合全程经口给药、联合全程经口给药加灌肠。网状Meta分析结果显示,在首次排便时间方面,西医常规措施联合早期经口给药短于常规西医措施,其均数差(
MD
)和95%置信区间(
CI
)为[-1.2(-1.90,-0.71)]天,联合早期灌肠短于西医常规措施[-1.49(-2.17,-0.82)]天,联合早期经口给药加灌肠短于西医常规措施[-1.70(-3.26,-0.13)]天;在治疗后肠功能恢复时间上,西医常规措施联合早期经口给药短于西医常规措施[-2.02(-2.87,-1.45)]天,联合早期经口给药加灌肠短于西医常规措施[-2.10(-2.79,-1.46)]天。在腹腔内压方面,联合早期灌肠治疗后IAP低于西医常规措施[-2.12(-4.00,-0.20)]mg/L。西医常规措施联合承气汤类方治疗SAP在感染率、MODS发生率及死亡率方面均低于西医常规措施,而有效率则高于西医常规措施。干预措施的SUCAR排序结果显示,西医常规措施联合承气汤类方早期经口给药加灌肠对首次排便时间、肠功能恢复时间效果最好;西医常规措施联合承气汤类方全程治疗对感染率、MODS发生率、有效率和死亡率效果最好。
结论
2
西医常规措施联合承气汤类方治疗SAP更有利于提高临床疗效,在承气汤类方临床应用上不仅要重视早期干预,也应关注全程治疗,重视肠黏膜屏障功能的恢复;在给药途径上不仅要重视口服,也应重视局部灌肠给药,尤其是在SAP早期阶段。
Objective
2
To systematically evaluate the effect of
Chengqi Decoction
(承气汤) series (CDs) in different administration ways and at different medication time on the intestinal function and prognosis of severe acute pancreatitis (SAP).
Methods
2
Eligible randomized controlled trials (RCTs) were identified by searching PubMed, Embase, Cochrane Library, Web of science, SinoMed, Wanfang, CNKI, and VIP databases from inception dates to January 31st, 2020. Risk of bias tool recommended by the Cochrane Handbook 6.0 was used to assess the metho-dological quality of the RCTs. R 3.6.3 software and Stata 15 were used to perform analyses on the primary outcomes (time to first defecation, time to recovery of intestinal function and the secondary outcomes including intraperitoneal pressure (IAP), C-reactive protein (CRP), incidences of infection, multiple organ dysfunction syndrome (MODS), effectiveness rate and mortality). The treatments can be ranked by the surface under the cumulative ranking curve (SUCRA). Egger's test and Begg's test were conducted to test for publication bias.
Results
2
Twenty-seven RCTs of 1825 patients were included, involving six treatments which were regular western medicine alone (WM), WM with and WM in combination with early oral administration of CDs (Early-O), WM with early enema of CDs (Early-E), early oral and enema of CDs (Early-OE), whole-course oral CDs (Whole-O), and whole-course oral and enema of CDs (Whole-OE). The network meta-analysis results showed that the time to first defecation was shorter in Early-O group (
MD
-1.2, 95%
CI
-1.90 to -0.71), Early-E group (
MD
-1.49, 95%
CI
-2.17 to -0.82), and Early-OE group (
MD
-1.70, 95%
CI
-3.26 to -0.13) compared to WM group. In terms of time to recovery of intestinal function, both Early-O group (
MD
-2.02, 95%
CI
-2.87 to -1.45) and Early-OE group (
MD
-2.10, 95%
CI
-2.79 to -1.46) were shorter than WM group. Early-E group had lower level of IAP than WM (
MD
-2.12, 95%
CI
-4.00 to -0.20). WM in combination with CDs had decreased incidences of infection and MODS, and mortality, as well as increased effective rate than WM alone. The SUCAR results showed that Early-OE worked best on time to first defecation and time to recovery of intestinal function, and Whole-OE had best effects on incidences of infection and MODS, effective rate and mortality.
Conclusion
2
The combination of WM and CDs showed better effect for treatment of SAP, and early-phase and whole-course intervention is important in clinical application. The recovery of the intestinal mucosal barrier function should be concerned. Both oral administration and local enema are significant, especially in the early stage of SAP.
张声生 , 李慧臻 . 急性胰腺炎中医中医诊疗专家共识意见(2017) [J]. 中华中医药杂志 , 2017 , 32 ( 9 ): 4085 - 4088 .
粱紫恩 , 韩莉 , 韦宏成 , 等 . 通腑泄热中药治疗急性胰腺炎的系统评价 [J]. 世界中医药 , 2018 , 13 ( 7 ): 1799 - 1803 .
彭鸿 , 陈国忠 , 方丽娇 , 等 . 清解化攻法合并高强度综合治疗在重症急性胰腺炎早期的作用 [J]. 辽宁中医杂志 , 2019 , 46 ( 5 ): 991 - 994 .
钦丹萍 , 金艳 , 杨强 , 等 . 规范并全程应用通腑导滞法治疗重度急性胰腺炎阳明腑实证临床观察 [J]. 中医杂志 , 2018 , 59 ( 7 ): 586 - 590 .
CUMPSTON M , LI T , PAGE M , et al . Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions [J]. Cochrane Database Syst Rev , 2019 , 10 : ED000142 . doi: 10.1002/14651858.ed000142 http://dx.doi.org/10.1002/14651858.ed000142 .
DIAS S , WELTON NJ , CALDWELL DM , et al . Checking consistency in mixed treatment comparison meta-analysis [J]. Stat Med , 2010 , 29 ( 7/8 ): 932 - 944 .
SALANTI G , ADES AE , IOANNIDIS JP . Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis:an overview and tutorial [J]. J Clin Epidemiol , 2011 , 64 ( 2 ): 163 - 171 .
潘万能 , 徐刚 , 叶宇 , 等 . 全疗程中西医结合治疗重症急性胰腺炎的疗效观察 [J]. 四川中医 , 2006 , 24 ( 10 ): 47 - 48 .
卞义博 . 清胰汤联合西药治疗重症急性胰腺炎的临床观察 [J]. 中外医疗 , 2008 , 27 ( 21 ): 109 - 129 .
CHEN H , LI F , JIA JG , et al . Effects of traditional Chinese medicine on intestinal mucosal permeability in early phase of severe acute pancreatitis [J]. Chin Med J (Engl) , 2010 , 123 ( 12 ): 1537 - 1542 .
沈卫标 , 周晓虹 . 加味承气汤对重症急性胰腺炎患者IL-6、IL-8、TNF-α水平的影响 [J]. 山东中医药大学学报 , 2011 , 35 ( 2 ): 40 - 41 .
WAN MH , LI J , HUANG W , et al . Modified Da-Cheng-Qi Decoction reduces intra-abdominal hypertension in severe acute pancreatitis: a pilot study [J]. Chin Med J (Engl) , 2012 , 125 ( 11 ): 1941 - 1944 .
赵园 . 大承气汤治疗重症急性胰腺炎23例 [J]. 中国当代医药 , 2012 , 19 ( 35 ): 108 - 109 .
钟雄利 , 谭小燕 , 任伟旺 , 等 . 大承气汤联合西医治疗重症急性胰腺炎的疗效及其对肠黏膜屏蔽功能的影响 [J]. 中国中西医结合消化杂志 , 2015 , 23 ( 4 ): 242 - 244 .
罗少媚 , 叶营 , 陈华梅 . 中药清胰汤治疗重症急性胰腺炎的临床观察 [J]. 中国实用医药 , 2015 , 10 ( 1 ): 161 - 162 .
甄威 , 许多 , 姜春梅 , 等 . 通腑清胰汤治疗急性重症胰腺炎临床研究 [J]. 中国中医急症 , 2016 , 25 ( 1 ): 8 - 9 .
赵伯贤 . 大承气汤对重症急性胰腺炎患者血清IL-6、TNF-α和CRP的影响 [J]. 浙江中医杂志 , 2016 , 51 ( 10 ): 713 - 714 .
吴燕飞 . 柴胡承气汤联合奥曲肽治疗重症急性胰腺炎的临床观察及对胃肠功能恢复的影响 [J]. 四川中医 , 2018 , 36 ( 7 ): 118 - 121 .
杨小青 . 大承气汤联合西药治疗重症急性胰腺炎胃肠功能障碍(阳明腑实)随机平行对照研究 [J]. 实用中医内科杂志 , 2018 , 32 ( 3 ): 20 - 23 .
田明 , 孙清露 , 陈振宙 , 等 . 经空肠注入通腑汤对重症急性胰腺炎患者胃肠功能的影响及机制研究 [J]. 中国临床医生杂志 2018 , 46 ( 3 ): 291 - 293 .
ZHANG MJ , ZHANG GL , YUAN WB , et al . Treatment of abdominal compartment syndrome in severe acute pancreatitis patients with traditional Chinese medicine [J]. World J Gastroenterol , 2008 , 14 ( 22 ): 3574 - 3578 .
刘炳炜 , 杨建锋 , 刘长文 , 等 . 柴芍承气汤灌肠辅助治疗重症急性胰腺炎合并腹腔间隔室综合征患者10例疗效观察 [J]. 中医杂志 , 2016 , 57 ( 4 ): 319 - 323 .
马建波 . 柴芍承气汤治疗重症急性胰腺炎合并腹腔间隔室综合征的疗效及作用机制探讨 [J]. 环球中医药 , 2018 , 11 ( 8 ): 1258 - 1260 .
易琼 , 戴飞跃 , 郭志华 , 等 . 加味大承气汤保留灌肠辅助治疗重症急性胰腺炎并发急性呼吸窘迫综合征腑实热结证45例临床观察 [J]. 中医杂志 , 2019 , 60 ( 19 ): 1657 - 1662 .
赵翟 , 粱鲁 , 穆托航 , 等 . 柴芍承气汤加味灌肠对重症急性胰腺炎患者胃肠功能及血清胰淀粉酶的影响 [J]. 中国中医急症 , 2019 , 28 ( 6 ): 1084 - 1086 .
徐艳琴 , 朱海超 , 李进 , 等 . 不同给药方式的大承气汤治疗重症急性胰腺炎临床研究 [J]. 国医论坛 , 2019 , 34 ( 3 ): 23 - 25 .
WU W , GUO J , YANG XN , et al . Effect of Chaiqinchengqi decoction on serum amyloid A in severe acute pancreatitis patients [J]. Asian Pac J Trop Med , 2012 , 5 ( 11 ): 901 - 905 .
董秀云 , 徐文浩 . ICU中西医结合内科治疗重症急性胰腺炎疗效观察 [J]. 中国现代医学杂志 , 2012 , 22 ( 2 ): 88 - 90 .
赵彬 . 中西医结合治疗重症急性胰腺炎30例 [J]. 中医研究 , 2012 , 25 ( 11 ): 40 - 41 .
李萍 , 孙华 , 刘林东 . 中西医结合治疗重症急性胰腺炎36例临床观察 [J]. 云南中医中药杂志 , 2013 , 34 ( 5 ): 25 - 26 .
肖高健 , 游旭东 , 王战波 , 等 . 早期应用中药清胰汤治疗重症急性胰腺炎42例疗效观察 [J]. 中国中医急症 , 2013 , 22 ( 7 ): 1211 - 1212 .
黄弘 , 高彩霞 . 中西医结合救治重症急性胰腺炎40例疗效观察 [J]. 新中医 , 2015 , 47 ( 2 ): 112 - 114 .
拉巴潘多 , 洛桑坚参 . 中西医结合治疗重症急性胰腺炎的临床疗效观察 [J]. 现代养生 , 2014 , 19 ( 2 ): 107 .
张汯 . 大承气汤加味治疗重症急性胰腺炎合并胃肠功能障碍的效果观察 [J]. 临床合理用药杂志 , 2019 , 12 ( 7 ): 57 - 59 .
WEI AL , GUO Q , WANG MJ , et al . Early complications after interventions in patients with acute pancreatitis [J]. World J Gastroenterol , 2016 , 22 ( 9 ): 2828 - 2836 .
WU LM , SANKARAN SJ , PLANK LD , et al . Meta-analysis of gut barrier dysfunction in patients with acute pancreatitis [J]. Br J Surg , 2014 , 101 ( 13 ): 1644 - 1656 .
DING L , CHEN HY , WANG JY , et al . Severity of acute gastrointestinal injury grade is a good predictor of mortality in critically ill patients with acute pancreatitiss [J]. World J Gastroenterol , 2020 , 26 ( 5 ): 514 - 523 .
DIMIDI E , CHRISTODOULIDES S , SCOTT SM , et al . Mechanisms of Action of Probiotics and the Gastrointestinal Microbiota on Gut Motility and Constipation [J]. Adv nutr (Bethesda, Md) , 2017 , 8 ( 3 ): 484 - 494 .
DE WAELE J , LEPPÄNIEMI A . Intra-abdominal hypertension in acute pancreatitis [J]. World J Surg , 2009 , 33 ( 6 ): 1128 - 1133 .
DIBIROV MD , ISAEV AI , JADJIEV AB , et al . Role of correction of the syndrome of intestinal failure and abdominal hypertension in the prevention of infection of pancreatic necrosis [J]. Khirurgiia , 2016 , 8 : 67 - 72 . doi: 10. 17116/hirurgia2016867-72 http://dx.doi.org/10.17116/hirurgia2016867-72 .
AGARWALA R , RANA SS , SHARMA RK , et al . Gastrointestinal Failure is a Predictor of Poor Outcome in Patients with Acute Pancreatitis [J]. Dig Dis and Sci , 2020 , 65 ( 8 ): 2419 - 2426 .
STAUBLI SM , OERTLI D , CHRISTINA AN . Laboratory markers predicting severity of acute pancreatitis [J]. Crit Rev Clin Lab Sci , 2015 , 52 ( 6 ): 273 - 283 .
YARKAÇ A , KOSE A , BOZKURT BABUŞ S , et al . The value of hematological parameters in acute pancreatitis [J]. Ulus Travma Acil Cerrahi Derg , 2019 , 25 ( 5 ): 453 - 460 .
MIAO B , LI FW , ZHANG SW , et al . Efficacy and safety of Tongfu powder in acute pancreatitis patients with gastrointestinal dysfunction: a clinical trial [J]. Drug Des Devel Ther , 2018 , 12 : 3665 - 3673 . doi: 10.2147/DDDT.S163645 http://dx.doi.org/10.2147/DDDT.S163645 .
0
浏览量
0
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号